Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer : An italian multicenter retrospective study

International Journal of Gynecological Cancer

Volumn 23, Issue 3, 2013, Pages 461-468

  Gadducci, Angiolo ^a   Cosio, Stefania ^a   Zola, Paolo ^b   Sostegni, Benedetta ^c   Fuso, Luca ^b   Sartori, Enrico ^c  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Chemotherapy; Early stage ovarian cancer; Pattern of failure; Surgery; Time to recurrence

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL;

ABDOMEN; ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; PELVIS; PRIORITY JOURNAL; RECURRENT CANCER; RETROPERITONEUM;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84876240867     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318286665b     Document Type: Article

References (33)

1. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95:S161-S192.
2. Trimbos JB, Vergote I, Bolis G, et al EORTC-ACTION Collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003;95:113-125.
3. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol. 2006;60:159-179.
4. Maggioni A, Benedetti Panici P, Dell'Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95:699-704.
5. Powless CA, Aletti GD, Bakkum-Gamez JN, et al. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: Implications for surgical staging. Gynecol Oncol. 2011;122:536-540.
6. Cress RD, Bauer K, O'MalleyCD, et al. Surgical staging of early stage epithelial ovarian cancer: Results from the CDC-NPCR ovarian patterns of care study. Gynecol Oncol. 2011;12:94-99.
7. Shroff R, Brooks RA, Zighelboim I, et al. The utility of peritoneal biopsy and omentectomy in the upstaging of apparent early ovarian cancer. Int J Gynecol Cancer. 2011;21:1208-1212.
8. Ng JS, Low JJ, Ilancheran A. Fertility preservation in gynaecological cancer: Epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2012;26:337-345.
9. Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol. 1995;6:887-893.
10. Tropé C, Kaern J, Hogberg T, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol. 2000;11:281-288.
11. Trimbos JB, ParmarM,Vergote I, et al. InternationalCollaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy in Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105-112.
12. Colombo N, Guthrie D, Chiari S, et al International Collaborative Ovarian Neoplasm (ICON). International Collaborative Ovarian Neoplasm trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003;95:125-132.
13. Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2009:CD004706.
14. Trimbos B, Timmers P, Pecorelli S, et al. Surgical staging and treatment of early ovarian cancer: Long-term analysis from a randomized trial. J Natl Cancer Inst. 2010;102:982-987.
15. Bell J, Brady MF, Young RC, et al Gynecologic Oncology Group. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2006;102:432-439.
16. Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:301-306.
17. Adams G, Zekri J, Wong H, et al. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: Single or combination chemotherapy? BJOG. 2010;117:1459-1467.
18. Bamias A, Karadimou A, Soupos N, et al. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: A single institution experience. Gynecol Oncol. 2011;123:37-42.
19. Gadducci A, Sartori E, Maggino T, et al. Analysis of failures in patients with stage I ovarian cancer: An Italian multicenter study. Int J Gynecol Cancer. 1997;7:445-450
20. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357:176-182.
21. Chan JK, Tian C, Monk BJ, et al Gynecologic Oncology Group. Prognostic factors for high-risk early stage epithelial ovarian cancer: A Gynecologic Oncology Group study. Cancer. 2008;112:2202-2210.
22. Paulsen T, Krn J, Tropé C. Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery. Gynecol Oncol. 2011;122:83-88.
23. Chan JK, Tian C, Teoh D, et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:307-311.
24. Kolomainen DF, A'Hern R, Coxon FY, et al. Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? J Clin Oncol. 2003;21:3113-3118.
25. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
26. Gadducci A, Cosio S, Conte PF, et al. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. Crit Rev Oncol Hematol. 2005;55:153-166.
27. Taylor AE, Wiltshaw E, Gore ME, et al. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol. 1994;12:2066-2070.
28. Gore M, Mainwaring P, A'Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecol Oncol Group J Clin Oncol. 1998;16:2426-2434.
29. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351:2489-2497.
30. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933-1939.
31. Salani R, Santillan A, ZahurakML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: Analysis of prognostic factors and survival outcome. Cancer. 2007;109:685-691.
32. Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21:289-295.
33. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702-1710.